logo-loader
viewRedx Pharma Plc

Redx Pharma plc - Result of General Meeting

RNS Number : 4842A
Redx Pharma plc
21 January 2020
 

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

REDX PHARMA PLC

("Redx" or "the Company")

 

Result of General Meeting

 

Alderley Park, 21 January 2020 Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that at the General Meeting of the Company held earlier today, all resolutions put to the meeting were duly passed.

 

As a consequence of the capitalisation of the loan agreement (the "Loan") with Moulton Goodies Limited ("MGL") as announced on 31 December 2019, 52,030,789 new ordinary shares will be issued and allotted to MGL on 22 January 2020. At such point the Loan will have been discharged in full and cease to be a debt of the Company meaning there will be no requirement on the Company to repay the Loan or any other amount to MGL.

 

Following admission on 22 January 2020 of the 52,030,789 new ordinary shares and in accordance with Rule 2.9 of the City Code on Takeovers and Mergers, the Company confirms that, it will have 178,508,703 ordinary shares of 1p each in issue. The Company holds no ordinary shares in treasury. Accordingly, the total number of voting rights in Redx will be 178,508,703. The International Identification Number ("ISIN") for Redx's ordinary shares is GB00BSNB6S51.

 

The table below sets out the details of the votes put to shareholders, with resolution 3 being duly passed on a poll:

 

Resolution number

Resolution name

Number of votes for & discretionary

% of votes for & discretionary

Number of votes against

% of votes against

% votes withheld

Total votes cast (including withheld)

1

Allot shares

66,792,243

99.99%

4,486

0.01%

0.01%

66,801,730

2

Pre-emption rights

66,792,243

99.99%

4,486

0.01%

0.01%

66,801,730

3

Rule 9 waiver

43,824,136

99.99%

4,486

0.01%

0.01%

43,833,624

 

 

For further information, please contact:

 

Redx Pharma Plc

T: +44 1625 469 920

Lisa Anson, Chief Executive Officer

 

James Mead, Chief Financial Officer

 

 

 

Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker)

T: +44 20 7894 7000

Phil Davies

 

 

 

WG Partners LLP (Joint Broker and Financial Adviser)

T: +44 20 3705 9330

Claes Spång/Chris Lee/David Wilson

 

 

 

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Ciara Martin

 

 

 

About Redx Pharma Plc 

Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ROMUAAORRKUAUAR

Quick facts: Redx Pharma Plc

Price: 8.75

Market: AIM
Market Cap: £15.62 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma's chief scientific officer talks grant funding for its fibrosis...

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...

on 19/11/19